{"title":"以硫酸肝素为基础的新蛋白多糖用于靶向溶酶体降解淀粉样蛋白-β","authors":"Sharath S. Vishweshwara, Saurabh Anand, Preeti Ravindra Bhoge, Virendrasinh Mahida, Ankita Chandra, Srinivas Vinod Saladi, Raghavendra Kikkeri","doi":"10.1021/acs.jmedchem.5c00845","DOIUrl":null,"url":null,"abstract":"Targeted lysosomal degradation of proteins (LDP) represents a promising strategy for clearing unwanted toxic extracellular and secreted proteins. Yet, significant challenges persist, including identifying potential ligands for these proteins and lysosome-driving probes capable of facilitating their internalization and degradation through receptor-mediated endocytosis. Herein, we show that synthetic neoproteoglycan probes stably anchor to the cell membrane, facilitate the internalization of amyloid-β (Aβ) peptide into the lysosomal compartment, and mediate the programmed death of Aβ. We have identified sulfated oligo <span>l</span>-idose tetrasaccharide (<b>ID49</b>) and heparan sulfate hexasaccharides (<b>HH26S</b>) as potential ligands for Aβ<sub>1–42</sub> peptide. When these molecules are expressed on the peptide-based fluorescent neoproteoglycan backbone, <b>PG@HH26S</b> persists on the cell membrane and facilitates Aβ<sub>1–42</sub> endocytosis to the lysosomal compartment and subsequent targeted degradation of Aβ<sub>1–42</sub>. Overall, neoproteoglycans open a new avenue to generate LDP for degrading HS-binding proteins, including growth factors, morphogens, and toxic secreted proteins.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"41 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Heparan Sulfate-Based Neoproteoglycan for Targeted Lysosomal Degradation of Amyloid-β\",\"authors\":\"Sharath S. Vishweshwara, Saurabh Anand, Preeti Ravindra Bhoge, Virendrasinh Mahida, Ankita Chandra, Srinivas Vinod Saladi, Raghavendra Kikkeri\",\"doi\":\"10.1021/acs.jmedchem.5c00845\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Targeted lysosomal degradation of proteins (LDP) represents a promising strategy for clearing unwanted toxic extracellular and secreted proteins. Yet, significant challenges persist, including identifying potential ligands for these proteins and lysosome-driving probes capable of facilitating their internalization and degradation through receptor-mediated endocytosis. Herein, we show that synthetic neoproteoglycan probes stably anchor to the cell membrane, facilitate the internalization of amyloid-β (Aβ) peptide into the lysosomal compartment, and mediate the programmed death of Aβ. We have identified sulfated oligo <span>l</span>-idose tetrasaccharide (<b>ID49</b>) and heparan sulfate hexasaccharides (<b>HH26S</b>) as potential ligands for Aβ<sub>1–42</sub> peptide. When these molecules are expressed on the peptide-based fluorescent neoproteoglycan backbone, <b>PG@HH26S</b> persists on the cell membrane and facilitates Aβ<sub>1–42</sub> endocytosis to the lysosomal compartment and subsequent targeted degradation of Aβ<sub>1–42</sub>. Overall, neoproteoglycans open a new avenue to generate LDP for degrading HS-binding proteins, including growth factors, morphogens, and toxic secreted proteins.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c00845\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00845","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Heparan Sulfate-Based Neoproteoglycan for Targeted Lysosomal Degradation of Amyloid-β
Targeted lysosomal degradation of proteins (LDP) represents a promising strategy for clearing unwanted toxic extracellular and secreted proteins. Yet, significant challenges persist, including identifying potential ligands for these proteins and lysosome-driving probes capable of facilitating their internalization and degradation through receptor-mediated endocytosis. Herein, we show that synthetic neoproteoglycan probes stably anchor to the cell membrane, facilitate the internalization of amyloid-β (Aβ) peptide into the lysosomal compartment, and mediate the programmed death of Aβ. We have identified sulfated oligo l-idose tetrasaccharide (ID49) and heparan sulfate hexasaccharides (HH26S) as potential ligands for Aβ1–42 peptide. When these molecules are expressed on the peptide-based fluorescent neoproteoglycan backbone, PG@HH26S persists on the cell membrane and facilitates Aβ1–42 endocytosis to the lysosomal compartment and subsequent targeted degradation of Aβ1–42. Overall, neoproteoglycans open a new avenue to generate LDP for degrading HS-binding proteins, including growth factors, morphogens, and toxic secreted proteins.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.